Mitochondrial peptides: MOTS-c and the early map

Mitochondria still encode a handful of peptides. That fact is interesting on its own. MOTS-c, a 16-amino-acid peptide from the 12S rRNA region, entered metabolism research in 2015 as a circulating factor that looked, in mice, a little like an exercise mimetic via AMPK-related pathways.

What is actually known

Lee, Cohen, and colleagues showed that MOTS-c is expressed, that it can be measured in circulation, and that in rodents it influences insulin sensitivity and metabolic stress responses. Human papers since then are mostly observational: levels versus age, versus metabolic status. That is a respectable early map. It is not a dosing guide.

The peptide that went to trial

If you want to see what 'serious' looks like in this neighborhood, look at elamipretide (SS-31): a mitochondria-targeted tetrapeptide that binds cardiolipin and has been run through modern programs in mitochondrial myopathy, Barth syndrome, and other indications. Some signals, several missed primaries, a still-unapproved drug. Mixed trial results are adult information. Vendor copy is not.

Longevity claims

Cellular-aging marketing will flatten MOTS-c, humanin, SS-31, and epithalon into one 'mitochondrial stack.' They do not share a receptor, a trial, or a risk profile. MOTS-c is a mitochondrial ORF product. Elamipretide is a synthetic cardiolipin ligand. Epithalon is a pineal-associated tetrapeptide with a telomerase story. Lumping them is how you stop thinking.

The mitochondria are not a brand. They are an organelle. Peptides that touch them still have to earn human evidence one indication at a time.